Optimal therapy in genotype 4 chronic hepatitis C: finally cured?

@article{AbdelRazek2015OptimalTI,
  title={Optimal therapy in genotype 4 chronic hepatitis C: finally cured?},
  author={W Abdel-Razek and Imam Waked},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  year={2015},
  volume={35 Suppl 1},
  pages={
          27-34
        }
}
Optimal therapy for patients with hepatitis C virus (HCV) genotype 4 (HCV-4) infection is changing rapidly, and the possibility of a total cure is near. The standard of care has been combination pegylated interferon (PEG-IFN)-ribavirin (RBV), with modest response rates and considerable adverse events. Since the introduction of sofosbuvir (SOF), simeprevir (SIM), and daclatasvir (DCV), the duration of treatment has been significantly shortened and response rates have increased. The recommended… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

Management of hepatitis C genotype 4 in the directly acting antivirals era

BMJ open gastroenterology • 2016
View 3 Excerpts
Highly Influenced

Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research • 2016
View 3 Excerpts
Highly Influenced

Mpviropack Plus : Real Life Study

Mohamed Baddar, Taher el Zanaty, +12 authors Mohamed B Hashem
2018
View 1 Excerpt

Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.

Liver international : official journal of the International Association for the Study of the Liver • 2017